ArticleFrontiers in oncology2025
Treatment patterns, outcomes, healthcare resource utilization, and costs associated with locally advanced squamous cell carcinoma of the head and neck in Japan.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Molecular and Cell Biological Characterization of Patient-Derived Head and Neck Squamous Carcinoma Cell Lines.Cancer science · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Treatment patterns and healthcare resource utilization (HCRU) data in patients with locally advanced (stage III to IVB) squamous cell carcinoma of the head and neck (LA SCCHN) in Japan are limited. This study describes the patient demographics and characteristics, treatment patterns, HCRU, and costs among Japanese patients with newly diagnosed LA SCCHN. Methods: This longitudinal, observational, retrospective study was conducted using real-world medical claims data from the Medical Data Vision Co., Ltd. database in Japan (1 January 2015-31 July 2022). Patients aged ≥18 years at the index date (first date of locally advanced head and neck cancer [HNC] diagnosis) and having a confirmed diagnosis of HNC during 01 January 2016-30 June 2021 in the oral cavity, larynx, hypopharynx, or oropharynx (based on ICD-10 diagnostic codes) were included. Baseline demographic and clinical characteristics were collected during the pre-index period. Treatment patterns, HCRU, and associated costs were reported during the post-index period. Results: Of the included 6741 patients with LA SCCHN, 51.3% received definitive nonsurgical treatment, 32.4% underwent primary resection, and 16.1% did not receive any agent. The most common chemotherapy agent used for chemoradiotherapy was cisplatin (74.7%). Docetaxel, cisplatin, and 5-fluorouracil combination (TPF) was used as induction chemotherapy for 28.6% of patients who received induction treatment followed by surgery and in 55.6% of patients who received induction treatment followed by radiotherapy. Patients receiving primary resection were typically older than those receiving definitive nonsurgical treatment for each cancer site and stage. Almost all patients had ≥1 all-cause hospitalizations with substantial HCRU-associated costs. Conclusions: This real-world study demonstrates that treatment of patients with LA SCCHN in Japan often included definitive nonsurgical treatment or primary surgery. The substantial burden related to LA SCCHN-associated HCRU and considerable percentage of patients receiving no treatment highlights a need for novel and effective therapies for LA SCCHN.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.